2-羟基-5-氟吡啶 | 51173-05-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-羟基-5-氟吡啶
• 中文别名: 5-氟-2-羟基吡啶
• 英文名称: 5-fluoropyridin-2-ol
• 英文别名: 5-fluoro-2-hydroxypyridine；2-hydroxy-5-fluoropyridine；5-fluoro-2-pyridinol；5-fluoro-1H-pyridin-2-one
• CAS: 51173-05-8
• 化学式: C₅H₄FNO
• mdl: MFCD03092918
• 分子量: 113.091
• InChiKey: KLULSYPVWLJZAO-UHFFFAOYSA-N

物化性质

• 熔点：
  150-155°C
• 沸点：
  251.7±40.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26,S39
• 危险类别码：
  R22,R37/38,R41
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险标志：
  GHS05,GHS07
• 危险性描述：
  H302,H315,H318,H335
• 危险性防范说明：
  P261,P280,P305 + P351 + P338
• 储存条件：
  室温

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-Fluoro-2-hydroxypyridine
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 51173-05-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin irritation (Category 2), H315
Serious eye damage (Category 1), H318
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22, R37/38, R41
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust.
P280 Wear protective gloves/ eye protection/ face protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 5-Fluoro-2-pyridinol
Formula : C5H4FNO
Molecular Weight : 113,09 g/mol
CAS-No. : 51173-05-8
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-Fluoro-2-hydroxypyridine
Acute Tox. 4; Skin Irrit. 2; Eye -
Dam. 1; STOT SE 3; H302,
H315, H318, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-Fluoro-2-hydroxypyridine
Xn, R22 - R37/38 - R41 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
no data available
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
no data available
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
no data available
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
For personal protection see section 8.
Environmental precautions
no data available
Methods and materials for containment and cleaning up
no data available
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
no data available
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
no data available

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 150 - 155 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,005
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
no data available

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Eye Dam. Serious eye damage
H302 Harmful if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
STOT SE Specific target organ toxicity - single exposure
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
R37/38 Irritating to respiratory system and skin.
R41 Risk of serious damage to eyes.

反应信息

• 作为反应物：
  描述：

  2-羟基-5-氟吡啶 在 硫酸 、 硝酸 、 N,N-二甲基甲酰胺 、 三溴氧磷 作用下， 以 四氢呋喃 、 DMF (N,N-dimethyl-formamide) 、 水 为溶剂， 反应 7.33h， 生成 4-氟-1H-吡咯并[2,3-c]吡啶-7-甲腈
  参考文献：
  名称：

  Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

  摘要：

  这项发明提供了具有药物和生物影响特性的化合物，它们的药物组合物和使用方法。具体而言，该发明涉及吡啶并咪唑酮乙酰基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染剂、免疫调节剂或HIV进入抑制剂结合使用。更具体地，本发明涉及治疗HIV和艾滋病。

  公开号：

  US20040110785A1
• 作为产物：
  描述：

  5-氨基-2-甲氧基吡啶 在 盐酸 、 tetrafluoroboric acid 、 sodium nitrite 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 反应 9.0h， 生成 2-羟基-5-氟吡啶
  参考文献：
  名称：

  Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 12. Structure–Activity Relationships Associated with 4-Fluoro-6-azaindole Derivatives Leading to the Identification of 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248)

  摘要：

  A series of highly potent HIV-1 attachment inhibitors with 4-fluoro-6-azaindole core heterocycles that target the viral envelope protein gp120 has been prepared. Substitution in the 7-position of the azaindole core with amides (12a,b), C-linked heterocycles (12c-I), and N-linked heterocycles (12m-u) provided compounds with subnanomolar potency in a pseudotype infectivity assay and good pharmacokinetic profiles in vivo. A predictive model was developed from the initial SAR in which the potency of the analogues correlated with the ability of the substituent in the 7-position of the azaindole to adopt a coplanar conformation by either forming internal hydrogen bonds or avoiding repulsive substitution patterns. 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248, 12m) exhibited much improved in vitro potency and pharmacokinetic properties than the previous clinical candidate BMS-488043 (1). The predicted low clearance in humans, modest protein binding, and good potency in the presence of 40% human serum for 12m led to its selection for human clinical studies.

  DOI：

  10.1021/jm3016377
• 作为试剂：
  描述：

  (2R,5R)-2-methyl-5-(toluene-4-sulfonyloxymethyl)piperidine-1-carboxylic cid tert-butyl ester 、 2-羟基-5-氟吡啶 在 2-羟基-5-氟吡啶 作用下， 以79的产率得到(2R,5R)-5-(5-fluoro-pyridin-2-yloxymethyl)-2-methylpiperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Org. Process Res. Dev. 2013, 17, 1, 61-68

  摘要：

  DOI：

文献信息

• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20150225379A1

  公开（公告）日：2015-08-13

  The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及环丙胺衍生物，这些衍生物是LSD1抑制剂，可用于治疗癌症等疾病。
• Novel 1,3,4-oxadiazole thioether derivatives containing flexible-chain moiety: Design, synthesis, nematocidal activities, and pesticide-likeness analysis
  作者：Jixiang Chen、Chengqian Wei、Sikai Wu、Yuqin Luo、Rong Wu、Deyu Hu、Baoan Song

  DOI：10.1016/j.bmcl.2020.127028

  日期：2020.4

  Seventy-two novel 1,3,4-oxadiazole thioether derivatives containing different flexible-chain moieties were designed and synthesized. The nematicidal activities of all the title compounds were evaluated, and some compounds showed excellent nematicidal activities against citrus nematodes. The compounds 15, 16, 18, 27, 41, 42, 44, 53, and 71 had the mortality to citrus nematodes of 92.5, 93.7, 90.3, 91

  设计并合成了72个含有不同柔性链部分的新型1,3,4-恶二唑硫醚衍生物。评价了所有标题化合物的杀线虫活性，并且某些化合物对柑橘线虫显示出优异的杀线虫活性。化合物15、16、18、27、41、42、44、53和71在浓度为5％时对柑橘线虫的死亡率为92.5％，93.7％，90.3％，91.5％，92.6％，92.8％，93.5％，91.3％和91.0％。 100 mg / L，优于阿维菌素对照剂（85.9％）。在测试浓度降至50 mg / L之后，化合物16、42、44、53和71的杀线虫活性仍优于阿维菌素（65.1％），死亡率分别为72.3、71.3、70.6、71.1，和73.9％。化合物16、42、44、53和71的LC50值为16.3、18.8、20.8、17.5，和14.7 mg / L，优于市售的阿维菌素阳性对照剂（24.8 mg / L）。同时，对农药样的定性和定量分析表明，化
• [EN] 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS<br/>[FR] 3 -AZABICYCLO [4.1.0] HEPTANES UTILISÉS COMME ANTAGONISTES DE L'OREXINE
  申请人：GLAXO GROUP LTD

  公开号：WO2010122151A1

  公开（公告）日：2010-10-28

  This invention relates to 3-azabicyclo[4.1.0] heptane derivatives (I) and their use as orexin receptor antagonists.

  这项发明涉及3-氮杂双环[4.1.0]庚烷衍生物(I)及其作为促觉醒素受体拮抗剂的用途。
• [EN] 5-METHYL-PIPERIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP DISORDER<br/>[FR] DÉRIVÉS DE 5-MÉTHYLPIPÉRIDINE COMME ANTAGONISTES DE RÉCEPTEURS À OREXINES POUR LE TRAITEMENT D'UN TROUBLE DU SOMMEIL
  申请人：GLAXO GROUP LTD

  公开号：WO2011023578A1

  公开（公告）日：2011-03-03

  This invention relates to heteroaryloxy 5-methyl substituted piperidine derivatives and their use as pharmaceuticals.

  这项发明涉及杂环氧基5-甲基取代哌啶衍生物及其作为药物的用途。
• 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors
  申请人：Merck Frosst Canada, Inc.

  公开号：US05698584A1

  公开（公告）日：1997-12-16

  The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

  这项发明涵盖了化合物I的新颖结构，可用于治疗环氧合酶-2介导的疾病。该发明还涵盖了用于治疗环氧合酶-2介导疾病的某些药物组合物，其中包括化合物I。